News Detail
Maryland, 19 Dec 2017: The U.S. Food and Drug Administration (FDA) is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients’ bodies, including......
View Details
Source : US FDA Safety Anouncement
Related News
- Interpol issues global alert on organised crime networks targeting COVID-19 vaccines (03-12-2020)
- Antibiotic Resistance May Be Halted by Cholesterol-Lowering Drug (03-12-2020)
- SII likely to sell Covid vaccine in private market by March-April (03-12-2020)
- Centre to revoke notification to allow export of Oseltamivir phosphate & Zanamivir (03-12-2020)
- It’s not honey: How the ‘magic syrup’ beat Indian testing protocols (03-12-2020)
- After Ramdev, Sri Sri Ravi Shankar launches herbal drug combo to ‘prevent & treat’ Covid (02-12-2020)
- 59% Indians sceptical about Covid-19 vaccine, won't rush to take it: Survey (02-12-2020)
- Initial findings into ''adverse event'' did not necessitate halting of trials: Govt (02-12-2020)
- Ayush medics can prescribe only for Covid prevention: Government (02-12-2020)
- Health ministry to amend NDCT Rules for registration of standalone BA labs (02-12-2020)